Dr Spero R Cataland (The Ohio State University, Wexner Medical Centre, Columbus, OH, USA) joins us for Rare Disease Day to discuss the importance of rapid diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder in which blood clots form in small blood vessels throughout the body. In this interview, Dr Cataland discusses the risks associated with aTTP, the long-term complications and the impact of living with this disease day to day.
Touch Medical Media is supporting Rare Disease Day (28 February 2022) to shine a light on healthcare inequalities for people living with Rare Diseases, focusing on patient quality of life and the difficulty of diagnosing patients early.
- Could you tell us about acquired/immune TTP and how it impacts patients’ daily lives? (0:35)
- Why is a rapid diagnosis of aTTP important for patients and what are the challenges in achieving this? (4:40)
- What are the current management options for patients with aTTP and what more is needed to prevent long-term complications and prevent relapse? (7:10)
Disclosures: Spero Cataland is a consultant to Sanofi and Takeda.
Support: The production of this video was supported by Touch Medical Media.
Other content available in support of Rare Disease Day includes:
- Damara Ortiz: The impact of Pompe disease and the importance of newborn screening
- Shekita Green: Living with neuromyelitis optica spectrum disorder (NMOSD) – A patient perspective
- Megan Hunter: Living with myasthenia gravis – A journey to diagnosis
- Ethan Crough: Living with achondroplasia – Celebrating diversity and increasing awareness
- Said Beydoun: Understanding myasthenia gravis and the impact on patients’ quality of life
- Jackie Palace: Improving diagnosis and treatment of neuromyelitis optica spectrum disorder
- Richard Keen, Rare Disease Day 2022: Rare bone diseases – Diagnosis, management and patient quality of life
Share this Video
Related Videos In Haematology
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!